Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
1. In January 2025, the U.S. will implement a 50% tariff on Chinese medical gloves, with a potential increase to 100% in 2026. Under a Donald Trump administration, this tariff could be revised to 100% as early as 2025, which would benefit Hartalega as a competitive advantage.
2. Hartalega has shown a consistent increase in sales volume on a quarter-over-quarter basis.
3. The weakening Malaysian Ringgit is advantageous for Hartalega, enhancing its export competitiveness.
4. Under potential Donald Trump policies in the oil and gas sector, commodity prices are likely to decline. Lower oil prices would reduce the cost of butadiene, a key raw material for Hartalega, as well as energy costs from natural gas.
5. Hartalega’s strong management and leadership, combined with a commitment to innovation and R&D, position it as a market leader in the nitrile glove segment.
6. Hartalega holds a strong net cash position of RM1.3 billion.
7. The company has resumed dividend payments, further enhancing its appeal to investors.
8. The U.S. is expected to impose tariffs on Chinese glove producers, even if they relocate manufacturing operations to other countries, providing a favorable competitive landscape for Hartalega.
9. Demand growth for nitrile gloves is expected to outpace supply in Q1 2025.
10. Hartalega is recognized for its highly efficient production processes and lowest manufacturing costs in the industry.
